Lukas M Carter
Overview
Explore the profile of Lukas M Carter including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
46
Citations
617
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Bauer D, Carter L, Atmane M, De Gregorio R, Michel A, Kaminsky S, et al.
J Nucl Med
. 2023 Nov;
65(1):109-116.
PMID: 37945380
Although pancreatic ductal adenocarcinoma (PDAC) is associated with limited treatment options and poor patient outcomes, targeted α-particle therapy (TAT) represents a promising development in the field. TAT shows potential in...
12.
Kurtz K, Eibler L, Dacek M, Carter L, Veach D, Lovibond S, et al.
Theranostics
. 2023 Nov;
13(15):5469-5482.
PMID: 37908719
The dynamics of CAR-T cells remain incompletely understood. Novel methods are urgently needed to longitudinally monitor transferred cells non-invasively for biodistribution, functionality, proliferation, and persistence and for improving their cytotoxic...
13.
Ocampo Ramos J, Carter L, Brown J, Marquis H, Uribe C, Zanzonico P, et al.
Med Phys
. 2023 Sep;
50(12):7390-7399.
PMID: 37656137
Background: Potential risk associated with low-dose radiation exposures is often expressed using the effective dose (E) quantity. Other risk-related quantities have been proposed as alternatives. The recently introduced risk index...
14.
Carter L, Zanzonico P
Res Sq
. 2023 Aug;
PMID: 37645915
Preclinical dosimetry is essential for guiding the design of animal radiopharmaceutical biodistribution, imaging, and therapy experiments, evaluating efficacy and/or toxicities in such experiments, ensuring compliance with ethical standards for animal...
15.
Kesner A, Carter L, Bolch W
J Nucl Med
. 2023 Aug;
64(10):1668.
PMID: 37562805
No abstract available.
16.
Pratt E, Lopez-Montes A, Volpe A, Crowley M, Carter L, Mittal V, et al.
Nat Biomed Eng
. 2023 Jul;
7(8):1028-1039.
PMID: 37400715
In conventional positron emission tomography (PET), only one radiotracer can be imaged at a time, because all PET isotopes produce the same two 511 keV annihilation photons. Here we describe...
17.
Kesner A, Carter L, Ocampo Ramos J, Lafontaine D, Olguin E, Brown J, et al.
J Nucl Med
. 2023 Jun;
64(7):1117-1124.
PMID: 37268428
Medical internal radiation dosimetry constitutes a fundamental aspect of diagnosis, treatment, optimization, and safety in nuclear medicine. The MIRD committee of the Society of Nuclear Medicine and Medical Imaging developed...
18.
Carter L, Ocampo Ramos J, Olguin E, Brown J, Lafontaine D, Jokisch D, et al.
J Nucl Med
. 2023 Jun;
64(8):1295-1303.
PMID: 37268423
Radiopharmaceutical dosimetry is usually estimated via organ-level MIRD schema-style formalisms, which form the computational basis for commonly used clinical and research dosimetry software. Recently, MIRDcalc internal dosimetry software was developed...
19.
Carter L, Bellamy M, Choi C, Kim C, Bolch W, Jokisch D, et al.
Health Phys
. 2023 May;
125(2):137-146.
PMID: 37195207
Current practice in reference internal dosimetry assumes a fixed upright standing posture is maintained throughout the dose-integration period. Recently, the mesh-type ICRP adult reference computational phantoms were transformed into different...
20.
Carter L, Krebs S, Marquis H, Ocampo Ramos J, Olguin E, Mason E, et al.
J Nucl Med
. 2023 Apr;
64(5):782-790.
PMID: 37074039
No abstract available.